Horizon Therapeutics PLC (NASDAQ:HZNP) insider Jeff Kent sold 3,545 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $36.50, for a total value of $129,392.50. Following the completion of the sale, the insider now directly owns 121,988 shares of the company’s stock, valued at approximately $4,452,562. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
HZNP stock opened at $36.37 on Wednesday. The company has a current ratio of 2.33, a quick ratio of 2.23 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $6.78 billion, a PE ratio of 17.25, a PEG ratio of 1.67 and a beta of 0.89. Horizon Therapeutics PLC has a 1-year low of $20.05 and a 1-year high of $36.77. The business’s 50 day simple moving average is $33.97 and its 200 day simple moving average is $28.39.
Horizon Therapeutics (NASDAQ:HZNP) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.14. Horizon Therapeutics had a return on equity of 27.71% and a net margin of 5.25%. The business had revenue of $335.50 million for the quarter, compared to analysts’ expectations of $330.60 million. During the same quarter in the prior year, the business earned $0.65 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. As a group, sell-side analysts predict that Horizon Therapeutics PLC will post 1.55 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System lifted its stake in shares of Horizon Therapeutics by 0.4% during the 3rd quarter. California State Teachers Retirement System now owns 292,915 shares of the biopharmaceutical company’s stock worth $7,976,000 after buying an additional 1,095 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Horizon Therapeutics by 45.7% during the 2nd quarter. Bank of Montreal Can now owns 3,831 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 1,201 shares during the period. Regent Investment Management LLC boosted its holdings in shares of Horizon Therapeutics by 0.9% during the 3rd quarter. Regent Investment Management LLC now owns 130,335 shares of the biopharmaceutical company’s stock worth $3,549,000 after buying an additional 1,225 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Horizon Therapeutics by 16.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,497 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 1,587 shares during the period. Finally, California Public Employees Retirement System grew its stake in Horizon Therapeutics by 0.8% in the 2nd quarter. California Public Employees Retirement System now owns 258,888 shares of the biopharmaceutical company’s stock valued at $6,229,000 after buying an additional 1,946 shares during the last quarter. 88.24% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently weighed in on the stock. Stifel Nicolaus boosted their target price on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, December 16th. Zacks Investment Research lowered shares of Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 price target on the stock. in a research report on Tuesday, October 29th. Cantor Fitzgerald increased their price target on shares of Horizon Therapeutics from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Bank of America assumed coverage on shares of Horizon Therapeutics in a research report on Thursday, September 26th. They issued a “buy” rating and a $34.00 price objective for the company. Finally, BMO Capital Markets lifted their price objective on shares of Horizon Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, December 16th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Horizon Therapeutics currently has an average rating of “Buy” and an average price target of $36.62.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Recommended Story: What is the market perform rating?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.